ArticleAmerican journal of translational research2025
Use of 16s RNA and metabolomics to investigate the therapeutic effect of Zhuyang Tongbian Decoction on mice with functional constipation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the therapeutic effects of Zhuyang Tongbian Decoction (ZTD) on vasoactive intestinal peptide (VIP) and 5-hydroxytryptamine receptor (5-HTR) in colon tissues, intestinal flora, and fecal metabolites in mice with functional constipation (FC).
methodsA total of 36 BALB/c mice were divided into six groups: control, model, positive (Cisapride), and ZTD groups with three dosages (1.5 g/mL, 3 g/mL, and 6 g/mL). All mice, except those in the control group, were induced with FC by gavage using the compound diphenoxylate. After establishing the model, each group received the respective treatments by gavage for two weeks. The laxative effect was evaluated by comparing changes in body weight, fecal weight, fecal water content, and the percentage of carbon powder propulsion in the small intestine. Immunohistochemistry was used to assess the distribution and expression of VIP and 5-HTR in proximal colon tissues. Additionally, 16S rRNA sequencing and liquid chromatography with quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) non-targeted metabolomics analysis were used to examine the effects of ZTD on intestinal flora composition and metabolites in FC mice.
resultsZTD treatment not only alleviated FC symptoms but also increased the number of VIP and 5-HTR-positive cells in colon tissues. Furthermore, ZTD improved the diversity and abundance of intestinal flora, significantly increasing the relative abundance of Prevotellaceae, Bacteroidales_S24-7_group, Ruminococcaceae, and Roseburia while reducing the abundance of Proteobacteria, Desulfovibrionaceae, Rikenellaceae, Porphyromonadaceae, and Erysipelotrichaceae. In terms of metabolites, ZTD significantly elevated the levels of deoxyadenosine and adenine, while significantly lowering the levels of L-leucine, L-threonine, succinate, tyramine, L-tyrosine, and dopamine.
conclusionsThis study provides a theoretical basis for the treatment of FC with ZTD. ZTD increased levels of the intestinal neurotransmitters VIP and 5-HTR and promoted the colonization of beneficial bacteria, including the dominant butyric acid-producing bacterium Roseburia. Additionally, ZTD reduced fecal dopamine levels, indicating its value as a therapeutic approach for FC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.